Incidence of HCV in volunteery blood donors of ABO blood group system in blood center jawaharlal medical College sawangi Meghe, wardha
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- The present study attempt to suggest patients to take a treatment of HCV
研究概览
简要总结
According to the World Health Organisation, complications from hepatitis killed 23,720 persons in Pakistan in 2016. ABO blood group variations affected how sensitive people were to various illnesses. People with blood types A and AB, for example, were more likely to experience severe malaria, whereas people with blood type O had higher levels of resistance to the protozoan agent.With almost half of the patients receiving neither treatment nor diagnosis,The hepatitis C virus continues to pose a major threat to public health. Chronic HCV is mainly responsible for cirrhosis, fibrosis, hepatocellular cancer, and other hepatic morbidities. On the basis of their ages, the study participants will be split into four groups. Patients in the first group ranged in age from 17 to 25 years old (52), while those in the second, third, and fourth groups ranged from 26 to 34 years old (92), 35 to 43 years old (42), and 44 years and older (14) respectively. Because average viral load in females was higher than in men, HCV Viremia had a more serious effect on females than on males. The experiences of HCV patients must be improved through increased societal awareness and gender-sensitive healthcare. An estimated 130 million people worldwide have the hepatitis C virus (HCV), the majority of whom are chronic carriers. People who have HCV infection are at risk for cirrhosis, primary hepatocellular carcinoma (HCC), and serving as a reservoir for the spread of the infection to others. According to estimates, cirrhosis affects 27% and HCC affects 25% of the global population, respectively. There is a good chance that HCV infection has been widespread for centuries numerous populations.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 55.00 Year(s)(—)
- 性别
- All
入选标准
- •All the Voluntary blood donors donating in AVBRH JNMC blood centre tested for HCV From October 2022 to July 2024.
排除标准
- •People who are not compatible for blood donation due to various reasons such as age, weight, Hemoglobin, disease, medication, etc.
结局指标
主要结局
The present study attempt to suggest patients to take a treatment of HCV
时间窗: 1 year, 10 months
次要结局
未报告次要终点
研究者
Aboli Awari
Datta Meghe Institute Of Higher Education and Research
